Modulation of cardiometabolic risk and CardioRenal syndrome by oral vitamin D 3 supplementation in Black and White Southern Sahara residents with chronic kidney disease Stage 3: focus on racial and ethnic disparities

• Published in: Renal failure 2022-12, Vol.44 (1), p.1243-1263
• Main Authors: Bouazza, Asma, Tahar, Amina, AitAbderrhmane, Samir, Saidani, Messaoud, Koceir, Elhadj-Ahmed
• Format: Article
• Language: English
• Subjects: Biomarkers; Cardio-Renal Syndrome - complications; Cardio-Renal Syndrome - ethnology; Cardio-Renal Syndrome - etiology; Cholecalciferol - administration & dosage; Cholecalciferol - therapeutic use; Dietary Supplements; Humans; Hyperparathyroidism, Secondary - complications; Hyperparathyroidism, Secondary - ethnology; Renal Insufficiency, Chronic; Troponin T; Vitamin D Deficiency
• ISSN: 0886-022X; 1525-6049
• DOI: 10.1080/0886022X.2022.2106244

Several studies have shown that cholecalciferol supplementation (25OHD-S) in chronic kidney disease (CKD) improves kidney injury by reducing fibrosis-related vascular calcification and declining apoptosis-linked nephron damage. The oral 25OHD-S was evaluated in 60,000 IU/month/36 weeks in 2000 IU/d/24 weeks in CKD Stage 3 with serum 25OHD level < 20 ng/mL. The study was undertaken on 156 black subjects and 150 white subjects Southern Sahara (SS). All biomarkers of cardiometabolic (CMet) and cardiorenal (CRenal) syndrome, Renin-angiotensin-aldosterone system (RAAS) profile, secondary hyperparathyroidism (SHPT), N-terminal pro B-type natriuretic peptide (NT-proBNP), Troponin T (cTnT) and atherogenicity risk were assessed by biochemical methods. Estimate glomerular filtration rate (eGFR) by chronic CKD-EPI equation formula. Total serum vitamin D by liquid chromatography-tandem mass spectrometry (MS). Vitamin D deficiency alters in the same manner CMet, CRenal, and others biomarkers in both groups SS; however, these disorders are more acute in blacks compared to whites SS. Oral 25OHD-S a highlighted improvement of eGFR drop, SHPT decrease, decline proteinuria, and cardiac failure risk (NT-proBNP and cTnT) attenuation. Concomitantly, 25OHD-S normalizes , , and (RAAS) activity. Nevertheless, homocysteine and Lp (a) do not modulate by 25OHD-S. The oral vitamin D3 supplementation, according the dose, and the treatment duration does not like in black-skinned people to white-skinned inhabitants, while the 02 groups are native to the same Saharan environment. It emerge that a high intermittent dose through an extensive supplementation (60,000 IU/36 weeks) was more effective in black subjects. At opposite, a lower dose during a short period supplementation is sufficient (2000 IU/24 weeks) in white subjects.